Association between patient characteristics and DAT result at entry
| Factor* . | DAT negative . | DAT positive . | P . |
|---|---|---|---|
| Age, no. (%) | |||
| Younger than 60 y | 178 (86) | 28 (14) | .4 |
| 60 to 69 y | 210 (88) | 29 (12) | |
| 70 y or older | 160 (83) | 32 (17) | |
| Stage, no. (%) | |||
| A progressive | 146 (93) | 11 (7) | <.001 |
| B | 245 (89) | 31 (11) | |
| C | 157 (77) | 47 (23) | |
| Sex, no. (%) | |||
| Female | 142 (86) | 24 (14) | .9 |
| Male | 406 (86) | 65 (14) | |
| Treatment, no. (%) | |||
| Chlorambucil | 272 (86) | 43 (14) | .9 |
| Fludarabine | 135 (87) | 21 (13) | |
| FC | 141 (85) | 25 (15) | |
| B2M, mg/L, median (range), n=484 | 3.6 (0.0–29.4) | 4.5 (1.3–11.3) | .001† |
| ALC, ×109/L, median (range), n=619 | 74 (1–570) | 107 (2–519) | .007† |
| LDH, U/L, median (range), n=598 | 415 (73–1953) | 424 (4–1135) | .9† |
| Factor* . | DAT negative . | DAT positive . | P . |
|---|---|---|---|
| Age, no. (%) | |||
| Younger than 60 y | 178 (86) | 28 (14) | .4 |
| 60 to 69 y | 210 (88) | 29 (12) | |
| 70 y or older | 160 (83) | 32 (17) | |
| Stage, no. (%) | |||
| A progressive | 146 (93) | 11 (7) | <.001 |
| B | 245 (89) | 31 (11) | |
| C | 157 (77) | 47 (23) | |
| Sex, no. (%) | |||
| Female | 142 (86) | 24 (14) | .9 |
| Male | 406 (86) | 65 (14) | |
| Treatment, no. (%) | |||
| Chlorambucil | 272 (86) | 43 (14) | .9 |
| Fludarabine | 135 (87) | 21 (13) | |
| FC | 141 (85) | 25 (15) | |
| B2M, mg/L, median (range), n=484 | 3.6 (0.0–29.4) | 4.5 (1.3–11.3) | .001† |
| ALC, ×109/L, median (range), n=619 | 74 (1–570) | 107 (2–519) | .007† |
| LDH, U/L, median (range), n=598 | 415 (73–1953) | 424 (4–1135) | .9† |